---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-070574"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:45:54.389700+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Geron receives FDA approval for RYTELO (imetelstat) in lower-risk MDS with transfusion-dependent anemia

## Summary
- RYTELO approved for low-to-int-1 risk MDS with TD anemia requiring ≥4 RBC units/8 wks who failed/are ineligible for ESAs.
- Phase 3 IMerge trial: 8-week RBC-TI 39.8% vs 15.0% placebo (p<0.001); 24-week RBC-TI 28.0% vs 3.3% (p<0.001).
- Median RBC-TI duration ~1 year for 8-week responders; ~1.5 years for 24-week responders.
- Most common Grade 3/4 adverse reactions: neutropenia (72%) and thrombocytopenia (65%), each lasting median <2 weeks.
- Conference call with Geron management scheduled for 8am ET on June 7, 2024 to discuss the approval and launch.

## SEC filing metadata
- accession: 0000950170-24-070574
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/0000950170-24-070574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024070574/gern-20240606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-070574
- JSON: https://secwatch.observer/filing/0000950170-24-070574.json
- Plain text: https://secwatch.observer/filing/0000950170-24-070574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.